From BioHealth Investor
Biotechnology
IDERA PHARMACEUTICAL [IDP] +9.90%
BIONOVO INC [BNVI.OB] +9.20%
CHELSEA THERAPEUTICS [CHTP] +9.00%
CURIS INC [CRIS] +7.58%
MICROMET INC [MITI] +5.78%
Diagnostic Substances
PALATIN TECH INC [PTN] +13.66%
AVALON PHARMACEUTIC [AVRX] +9.30%
SURMODICS INC [SRDX] +7.99%
SYNOVICS PHARMACEUTL [SYVC.OB] +7.69%
ADEZA BIOMEDICAL COR [ADZA] +5.19%
Drug Delivery
QUIGLEY CORP THE [QGLY] +3.62%
MATRIXX INITIATVS [MTXX] +3.12%
EMISPHERE TECH [EMIS] +2.83%
NOVEN PHARMACEUTIC [NOVN] +1.63%
DELCATH SYSTEMS INC [DCTH] +1.36%
Drug Manufacturers
ARQULE INC [ARQL] +7.97%
UNIGENE LABS INC [UGNE.OB] +6.35%
SIGA TECH INC [SIGA] +5.04%
NOVOGEN LTD ADS [NVGN] +4.81%
MARSHALL EDWARDS [MSHL] +4.73%
Medical Appliances & Equipment
HOLOGIC INC [HOLX] +13.84%
RESTORE MEDICAL INC [REST] +12.90%
THERAGENICS CORP [TGX] +12.50%
MEDICAL SOLUTION MGT [MSMT.OB] +10.00%
HANSEN MEDICAL, INC. [HNSN] +9.45%
Medical Instruments & Supplies
IMMUNOCELLULAR THERA [IMUC.OB] +73.91%
NEPHROS INC. [NEP] +19.51%
MILESTONE SCIENTIFIC [MLSS.OB] +15.15%
MICROMED CARDIOVASCU [MMCV.OB] +7.50%
ATRICURE, INC. [ATRC] +5.95%
Medical Laboratories & Research
ARRAY BIOPHARMA IN [ARRY] +3.07%
GENOMIC HEALTH, INC. [GHDX] +1.20%
ERESEARCHTECHNOLOG [ERES] +1.01%
RADNET INC [RDNT.OB] +1.01%
BIO-REFERENCE LAB [BRLI] +0.75%
http://www.biohealthinvestor.com/
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.